We used 266 clinical variables measured at 11 visits during 96 months comprising demographics, patient PD history, DaTSCAN imaging, non-motor symptoms, cerebrospinal fluid (CSF) biomarkers (A–β, α-synuclein, dopamine, phospho-tau, total tau) and UPDRS scores. The gene discussed is MAPT; the disease is Parkinson disease.